Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes?Claus, S. P. (2017) Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes? Cell Metabolism, 26 (1). pp. 6-7. ISSN 1550-4131 Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1016/j.cmet.2017.06.009 Abstract/SummaryGlucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.
Altmetric Funded Project Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |
Lists
Lists
